Hamdoon Musaab, Satchi Maria, Fawke Fay, Madaan Sanjeev
Department of Urology, Darent Valley Hospital, Dartford DA2 8DA, UK.
JRSM Open. 2021 Feb 19;12(2):2054270420983105. doi: 10.1177/2054270420983105. eCollection 2021 Feb.
Advanced and metastatic prostate cancer is often managed with hormonal blockage. Luteinising hormone-releasing hormone antagonists achieve rapid testosterone suppression and are used for the treatment of advanced or metastatic prostate cancer. Degarelix is a luteinising hormone-releasing hormone antagonist and is given as a loading dose, followed by a monthly maintenance dose. We report a case where a patient was inadvertently given a second loading dose of Degarelix that resulted in acute psychosis in the form of panic attacks, delusions, suicidal thoughts, insomnia and some visual hallucinations, which are not reported as side-effects of Degarelix.
晚期和转移性前列腺癌通常采用激素阻断治疗。促黄体生成素释放激素拮抗剂可迅速抑制睾酮,用于治疗晚期或转移性前列腺癌。地加瑞克是一种促黄体生成素释放激素拮抗剂,给药时先给予负荷剂量,随后每月给予维持剂量。我们报告了一例患者意外接受了第二剂地加瑞克负荷剂量,导致出现急性精神病症状,表现为惊恐发作、妄想、自杀念头、失眠以及一些视幻觉,而这些症状并未被报告为地加瑞克的副作用。